Summary of Financial Statements for the Three Month Period Ended June 30, 2015 (IFRS, Consolidated)

July 30, 2015

Takeda Pharmaceutical Company Limited Stock exchange listings: Tokyo, Nagoya, Fukuoka, Sapporo

TSE Code: 4502 URL: http://www.takeda.co.jp
Representative: Christophe Weber, President & CEO
Contact: Noriko Higuchi Telephone: +81-3-3278-2306
Global Finance, IR Head

Scheduled date of securities report submission: August 10, 2015
Scheduled date of dividend payment commencement: —
Supplementary materials for the financial statements: Yes
Presentation to explain for the financial statements: Yes

(Millions of JPY, rounded to the nearest million)

1. Consolidated Financial Results for the Three Month Period Ended June 30, 2015 (April 1 to June 30, 2015)

(1) Consolidated Operating Results (year to date)

(Percentage figures represent changes over the same period of the previous year)

	Revenue		Operating profit		Profit before tax		Net profit for the period	
	(Million JPY)	(%)	(Million JPY)	(%)	(Million JPY)	(%)	(Million JPY)	(%)
Three month period ended June 30, 2015	446,295	8.5	49,559	(22.2)	48,721	(18.8)	25,429	(25.9)
Three month period ended June 30, 2014	411,148	0.2	63,689	11.3	59,989	7.4	34,310	(6.2)

	Net profit attributable to owners of the Company		Total comprehensive income for the period		Basic earnings per share	Diluted earnings per share
	(Million JPY)	(%)	(Million JPY)	(%)	(JPY)	(JPY)
Three month period ended June 30, 2015	24,583	(26.4)	120,383	—	31.32	31.12
Three month period ended June 30, 2014	33,399	(7.1)	1,633	(98.8)	42.40	42.36

(2) Consolidated Financial Position

	Total assets (Million JPY)	Total equity (Million JPY)	Equity attributable to owners of the Company (Million JPY)	Ratio of equity attributable to owners of the Company to total assets (%)	Equity attributable to owners of the Company per share (JPY)
As of June 30, 2015	4,320,850	2,231,621	2,165,238	50.1	2,764.54
As of March 31, 2015	4,296,192	2,206,176	2,137,047	49.7	2,719.27

2. Dividends

	Annual dividends per share (JPY)				
	1st quarter end	2nd quarter end	3rd quarter end	Year-end	Total
Fiscal 2014	—	90.00	—	90.00	180.00
Fiscal 2015	—				
Fiscal 2015 (Projection)		90.00	—	90.00	180.00

(Note) Modifications in the dividend projection from the latest announcement: None

3. Forecasts for Consolidated Operation Results for Fiscal 2015 (April 1, 2015-March 31, 2016)

(Percentage figures represent changes from previous fiscal year.)

	Revenue		Operating profit		Profit before tax		Net profit attributable to owners of the Company		Basic earnings per share
	(Million JPY)	(%)	(Million JPY)	(%)	(Million JPY)	(%)	(Million JPY)	(%)	(JPY)
Fiscal 2015	1,820,000	2.4	105,000	—	115,000	—	68,000	—	86.53

(Note) Modifications in forecasts of consolidated operating results from the latest announcement: None

Additional Information

(1) Changes in significant subsidiaries during the period : No
(changes in specified subsidiaries resulting in the change in consolidation scope)

(2) Changes in accounting policies and changes in accounting estimates
1) Changes in accounting policies required by IFRS : Yes
2) Changes in accounting policies other than 1) : No
3) Changes in accounting estimates : No
(Note) For details, refer to "2. Additional Information in Summary" in page 10.

(3) Number of shares outstanding (common stock)
1) Number of shares outstanding (including treasury stock) at term end:

June 30, 2015	790,004,295 shares
March 31, 2015	789,923,595 shares

2) Number of shares of treasury stock at term end:

June 30, 2015	6,784,759 shares
March 31, 2015	4,032,165 shares

3) Average number of outstanding shares (for the three month period ended June 30):

June 30, 2015	785,026,072 shares
June 30, 2014	787,728,067 shares

* Implementation status about the audit

- This summary of financial statements is exempt from quarterly review procedures required by Financial Instruments and Exchange Act. A part of quarterly review for securities report based on Financial Instruments and Exchange Act has not completed at the time of disclosure of this summary of financial statements. The securities report for the three month period ended June 30, 2015 is scheduled to be disclosed on August 10, 2015 after completion of the quarterly review.

* Note to ensure appropriate use of forecasts, and other comments in particular

- All forecasts in this document are based on information currently available to the management, and do not represent a promise or guarantee to achieve those forecasts. Various uncertain factors could cause actual results to differ, such as changes in the business environment and fluctuation of foreign exchange rates. If a significant event occurs that requires the forecasts to be revised, the Company will disclose it in a timely manner.
- For details of the financial forecast, and the management guidance indicators for actual business performance, please refer to "1. Qualitative Information for the Three Month Period Ended June 30, 2015 (3) Outlook for Fiscal 2015" on page 8.
- Supplementary materials for the financial statements (presentation materials for the earnings release conference which is scheduled on July 30, 2015) and the audio of the conference including question-and-answer session will be promptly posted on the Company's website.
(Website of the Company)
http://www.takeda.com/investor-information/results/

Attachment Index

1. Qualitative Information for the Three Month Period Ended June 30, 2015

(1) Consolidated Operating Results
(i) Operating Results

Consolidated results (April 1 to June 30, 2015):

Billion JPY

	Amount	*Change over the same period of the previous year*	
Revenue	446.3	+35.1	+ 8.5%
R&D expenses	81.0	+5.8	+ 7.8%
Operating profit	49.6	- 14.1	- 22.2%
Profit before tax	48.7	- 11.3	- 18.8%
Net profit for the period (attributable to owners of the Company)	24.6	- 8.8	- 26.4%
EPS (JPY)	31.32	-11.08	- 26.1%

[Revenue]
Consolidated revenue was 446.3 billion JPY, an increase of 35.1 billion JPY (+8.5%) compared to the same period of the previous year.

- In Japan, sales of AZILVA (for hypertension) and LOTRIGA (for hyperlipidemia) significantly increased. In overseas markets, ENTYVIO (for ulcerative colitis and Crohn's disease), which was launched in several countries in 2014, has experienced strong sales growth, and in the U.S., sales of VELCADE (for multiple myeloma) and DEXILANT (for acid reflux disease) also increased. On the other hand, sales of large products such as CANDESARTAN (for hypertension) decreased mainly due to the penetration of generic products.
  In total, consolidated revenue increased by 35.1 billion JPY.
- Consolidated revenue of Takeda's major ethical drugs:

Billion JPY

Indications / Product Name	Amount	Change over the same period of the previous year	
Multiple myeloma / Velcade	42.3	+ 7.0	+19.9%
Prostate cancer, breast cancer and endometriosis / Leuprorelin (Japan product name: Leuplin)	30.9	+ 1.3	+4.5%
Peptic ulcer / Lansoprazole (Japan product name: Takepron)	25.9	+ 0.4	+1.7%
Peptic ulcer / Pantoprazole	24.3	- 1.5	-6.0%
Hypertension / Candesartan (Japan product name: Blopress)	22.7	- 13.8	-37.8%
Acid reflux disease / Dexilant	18.8	+ 6.2	+48.6%
Ulcerative colitis and Crohn's disease / Entyvio	16.2	+ 15.7	- %
Hypertension / Azilva	14.1	+ 4.4	+45.1%

(Note) Revenue amount includes royalty income and service income.

- In Japan, TAKECAB (for acid-related diseases) was launched in February 2015, and activities are currently ongoing to provide information about this product to healthcare professionals in co-promotion with Otsuka Pharmaceutical Company, Limited. Also in Japan, in May 2015, Takeda launched ZAFATEK, the world's first once weekly oral type 2 diabetes treatment option. In the U.S., in addition to ENTYVIO, prescriptions are steadily increasing for BRINTELLIX (for major depressive disorder) and CONTRAVE (for obesity), which were also launched last year. In Europe and Japan, ADCETRIS (for malignant lymphomas) is also experiencing steady sales growth.

[Operating profit]
Consolidated operating profit was 49.6 billion JPY, a decrease of 14.1 billion JPY (-22.2%) compared to the same period of the previous year.

- Gross profit increased by 32.1 billion JPY (+10.9%) due to revenue increase.
- Selling, general and administrative expenses increased by 25.1 billion JPY (+18.4%) mainly due to the increase in sales expenses related to new products in the U.S.
- R&D expenses were 81.0 billion JPY, an increase of 5.8 billion JPY (+7.8%) compared to the same period of the previous year.
- Other operating income decreased by 16.7 billion JPY, mainly due to 15.3 billion JPY of the gains on sales of property, plant and equipment being recognized in the same period of the previous year.

[Net profit for the period (attributable to owners of the Company)]
Consolidated net profit for the period was 24.6 billion JPY, a decrease of 8.8 billion JPY (-26.4%) compared to the same period of the previous year.

- In spite of the favorable impact of net financial income/expenses mainly due to the decrease in the loss on fair value remeasurements of contingent consideration liability, consolidated net profit for the period decreased due to the decrease in operating profit.
- Basic earnings per share was 31.32 JPY, a decrease of 11.08 JPY (-26.1%) compared to the same period of the previous year.

Underlying growth (Note1) (April 1 to June 30, 2015):

Billion JPY

	Change over the same period of the previous year	
Revenue	+ 6.1%	+ 25.7
Core Earnings (Note2)	- 0.1%	- 0.1
Core EPS (JPY) (Note3)	+ 0.0%	+ 0.00

(Note1) "Underlying Growth", comparing two years (or quarters) of financial results under common basis, shows the real performance of business. It excludes the impact of foreign exchange and exceptional items such as product divestments, impact of purchase accounting, amortization and impairment loss of intangible assets, restructuring costs and major litigation costs. Takeda adopts "Underlying Growth" of revenue, Core Earnings and Core EPS as its management guidance.

(Note2) Core Earnings is calculated from operating profit by excluding the impact of exceptional items, such as purchase accounting, amortization and impairment loss of intangible assets, restructuring costs and major litigation costs.

(Note3) Core EPS is earnings per share based on Core Net Profit that is calculated by excluding the impact of exceptional items that have the similar factors listed above and tax effects on them from Net profit for the period.

- Underlying revenue growth was +6.1% (+25.7 billion JPY) compared to the same period of the previous year.
- Underlying Core Earnings growth was flat at -0.1% compared to the same period of the previous year. Also, underlying selling, general and administrative expenses increased by 10.8% due to the increase of investment for new products and underlying R&D expenses increased by 6.7% due to the increase of expenses for some compounds.
- Underlying Core EPS growth was flat at +0.0% compared to the same period of the previous year.

(ii) Results by Segment

Revenue and operating profit by business segment (April 1 to June 30, 2015):

Billion JPY

Type of Business	Revenue		Operating profit	
	Amount	Change over the same period of the previous year	Amount	Change over the same period of the previous year
Ethical Drug	407.8	+35.4	34.9	+0.3
<Japan>	<135.0>	< - 3.0>		
<Overseas>	<272.8>	< +38.4>		
Consumer Healthcare	19.4	+2.5	7.6	+2.0
Other	19.1	-2.8	7.1	-16.4
Total	446.3	+35.1	49.6	-14.1

[Ethical Drug Business]

Revenue in the Ethical Drug Business was 407.8 billion JPY, an increase of 35.4 billion JPY (+9.5%) compared to the same period of the previous year, and operating profit was 34.9 billion JPY, an increase of 0.3 billion JPY (+0.9%) compared to the same period of the previous year.

- Revenue in Japan was 135.0 billion JPY, a decrease of 3.0 billion JPY (-2.1%) compared to the same period of the previous year. Contribution from sales increase of products such as AZILVA and LOTRIGA could not fully absorb the decrease in sales of BLOPRESS mainly due to the penetration of generic products.

- The following table shows revenue results of major products in Japan:

Billion JPY

Indications / Product Name	Amount	Change over the same period of the previous year	
Blopress (Hypertension)	16.1	- 12.8	-44.3%
Azilva (Hypertension)	14.1	+ 4.4	+45.1%
Leuplin (Prostate cancer, breast cancer and endometriosis)	13.3	- 1.0	-7.3%
Takepron (Peptic ulcer)	11.0	- 3.0	-21.4%
Nesina (Diabetes)	9.5	- 0.2	-2.3%
Lotriga (hyperlipidemia)	5.0	+ 3.1	+168.4%
Vectibix (Colorectal cancer)	4.7	+ 0.4	+9.0%
Reminyl (Alzheimer-type dementia)	3.9	+ 1.0	+36.4%

- Revenue in overseas markets was 272.8 billion JPY, an increase of 38.4 billion JPY (+16.4%) compared to the same period of the previous year. Despite some products decreasing in sales due to the penetration of generic products, this impact was fully absorbed by the stable sales increase of VELCADE and DEXILANT in the U.S., and also the sales contribution from new products such as ENTYVIO.

- The following table shows revenue results of major products in overseas markets:

Billion JPY

Indications / Product Name	Amount	Change over the same period of the previous year	
Velcade (Multiple myeloma)	41.0	+ 7.1	+21.1%
Pantoprazole (Peptic ulcer)	24.3	- 1.5	-6.0%
Dexilant (Acid reflux disease)	18.8	+ 6.2	+48.6%
Leuprorelin (Prostate cancer, breast cancer and endometriosis)	17.5	+ 2.4	+15.6%
Entyvio (Ulcerative colitis and Crohn’s disease)	16.2	+ 15.7	- %
Lansoprazole (Peptic ulcer)	14.9	+ 3.4	+30.0%
Colcrys (Gout)	11.2	- 3.2	-22.0%
Candesartan (Hypertension)	6.6	- 1.0	-12.8%

(Note) Revenue amount includes royalty income and service income.

[Consumer Healthcare Business]
Revenue in the Consumer Healthcare Business was 19.4 billion JPY, an increase of 2.5 billion JPY (+15.1%) compared to the same period of the previous year, mainly due to the increase in sales of ALINAMIN tablets (vitamin-containing products). Operating profit increased by 2.0 billion JPY (+34.3%) to 7.6 billion JPY mainly due to the increase in sales and the improvement in gross profit margin.

[Other Business]
Revenue in the Other Business was 19.1 billion JPY, a decrease of 2.8 billion JPY (-12.8%) compared to the same period of the previous year, mainly due to the end of sales contribution from the Mizusawa Group resulting from the sale of all shares held of Mizusawa Industrial Chemicals, Ltd. in April, 2015. Operating profit was 7.1 billion JPY, a decrease of 16.4 billion JPY (-69.9%), mainly due to 15.3 billion JPY of gains on sales of property, plant and equipment being recognized in the same period of the previous year.

(iii) Activities and Results of Research & Development

Takeda has aligned its research and development functions into the four Therapeutic Area Units (TAUs) of Central Nervous System, Cardiovascular/Metabolic, Gastroenterology, and Oncology, to further promote therapeutic area and asset strategies to achieve a global leadership position in each area, and to meet the unmet medical needs of patients. In addition, Specialty Business Units have been established for Oncology and Vaccines, which include operational and commercial functions.
Major events from R&D activities during the reporting period are as follows;

[In-house R&D activities]
- In April 2015, the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S. Food and Drug Administration (FDA) convened to review EXAMINE, a global cardiovascular safety outcomes trial of type 2 diabetes treatment NESINA (generic name: alogliptin), and voted that the use of alogliptin in patients with Type 2 diabetes has an acceptable CV risk profile. In June 2015, a post hoc analysis and additional post hoc analyses of data from EXAMINE were presented at the American Diabetes Association's (ADA) 75th Scientific Sessions.

- In May 2015, Takeda announced that it has started the Phase III Maintenance study (TOURMALINE-MM4 study) of MLN9708 (generic name: ixazomib), an investigational oral proteasome inhibitor, in patients with newly diagnosed multiple myeloma who have responded to initial therapy and have not undergone an autologous stem cell transplant.
  In July 2015, Takeda submitted a New Drug Application (NDA) to the FDA for MLN9708 for the treatment of patients with relapsed and/or refractory multiple myeloma. In July 2015, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted an accelerated assessment (*) to MLN9708 for the treatment of patients with relapsed and/or refractory multiple myeloma.
  (*) The EMA awards an accelerated assessment to those medicines deemed to be of major public health interest and, in particular, therapeutic innovation.

- In May 2015, Takeda announced that it has decided to discontinue the Phase III trial of MLN8237 (generic name: alisertib), an inhibitor of Aurora A kinase, for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) following the results of a pre-specified interim analysis that indicated the study is unlikely to meet the primary endpoint over the standard-of-care in this treatment setting. Takeda continues to investigate the utility of MLN8237 in small cell lung cancer.

[Alliance activities]

- In May 2015, Takeda announced that it has reached an agreement with Sumitomo Dainippon Pharma Co., Ltd. (Sumitomo Dainippon Pharma) to terminate the license agreement for the joint development and exclusive commercialization in Europe of LATUDA (generic name: lurasidone), an atypical antipsychotic agent. The companies are starting discussions in an effort to finalize and execute a mutual agreement establishing a transition plan for the orderly transfer of all development and commercialization rights and activities with respect to LATUDA to Sumitomo Dainippon Pharma.

[Joint Research activities]

- In April 2015, Takeda and the Center for iPS Cell Research Application (CiRA) of Kyoto University entered into a 10-year collaboration on iPS cell research. Takeda and CiRA will work together to develop clinical applications of induced pluripotent stem cells in areas such as heart failure, diabetes mellitus, neurological disorders and cancer immunotherapy. The “Takeda-CiRA Joint Program for iPS Cell Applications” (T-CiRA) is designed to expedite multiple research projects for drug discovery and cell therapy using iPS cells.

- In April 2015, Takeda announced that it has signed an agreement to undertake collaborative research with Keio University School of Medicine and Niigata University at Takeda's Shonan Research Center regarding the search for, and functional analysis of, disease-related RNA-binding proteins.

- In April 2015, Takeda and the National Cancer Center (NCC) of Japan signed a partnership agreement with the goal to discover and develop anti-cancer agents. Takeda and the NCC have agreed to share information and hold regular discussions in order to collaborate and transition findings from basic research to clinical research and development activities.

- In June 2015, Takeda and the Drugs for Neglected Diseases initiative (DNDi) have signed an agreement to collaborate in the “Lead Optimization Program” aimed at identifying the best compound among aminopyrazole series for developing an innovative drug for the treatment of visceral leishmaniasis. The program is being funded by Global Health Innovative Technology Fund.

[Improvement and Reinforcement of R&D organization]

- In June 2015, Takeda announced that it will consolidate its Vaccine Business Unit (VBU) operations by establishing global and regional hubs, as well as consolidating the U.S. vaccine sites, as the organization continues to grow and advance its important vaccine programs. The Boston/Cambridge, Massachusetts area, and Zurich, Switzerland will serve as VBU’s global hubs. VBU will maintain regional hubs in Singapore and in Brazil. Takeda will close its vaccine site in Bozeman, Montana as well as the Madison, Wisconsin and Fort Collins, Colorado sites. In addition, vaccine activities in Deerfield, Illinois, which currently serves as the global headquarters for VBU, will shift to the Boston/Cambridge area. This transition will occur in phases over the next two years, with the completion of U.S. consolidation by mid-2017.

(2) Consolidated Financial Position

[Assets]

Total assets as of June 30, 2015 were 4,320.8 billion JPY, an increase of 24.7 billion JPY compared to the previous fiscal year end.

[Liabilities]

Total liabilities as of June 30, 2015 were 2,089.2 billion JPY, a decrease of 0.8 billion JPY compared to the previous fiscal year end.

[Equity]

Total equity as of June 30, 2015 was 2,231.6 billion JPY, an increase of 25.4 billion JPY compared to the previous fiscal year end, which despite dividend payments, was mainly due to the increase in exchange differences on translation of foreign operations caused by the yen's depreciation as of June 30, 2015, in addition to net profit for the period.

The ratio of equity attributable to owners of the Company to total assets increased by 0.4 pt. to 50.1% from the previous fiscal year end.

(3) Outlook for Fiscal 2015

The outlook for consolidated results for the full year of fiscal 2015 has not been changed from the previous forecast (announced at the fiscal 2014 financial results announcement on May 15, 2015) as follows, considering the current results and others.

Forecast

Billion JPY

	Amount	*Change over the previous year*	
Revenue	1,820.0	+ 42.2	+2.4%
R&D expenses	330.0	- 52.1	-13.6%
Operating profit	105.0	+ 234.3	- %
Profit before income taxes	115.0	+ 260.4	- %
Net profit for the year (attributable to owners of the Company)	68.0	+ 213.8	- %
EPS (JPY)	86.53	+ 271.90	- %

Management Indicators – Underlying growth (*)

Revenue	Low single digit
Core Earnings (*)	Higher than revenue growth
Core EPS (*)	Higher than Core Earnings growth

(*) Please refer to the (Underlying growth) on page 4.

[Assumptions used in preparing the Outlook]

The foreign exchange rates assumptions for fiscal 2015 are 1 USD = 120 JPY and 1 EUR = 130 JPY.

[Forward looking statement]

All forecasts in this document are based on information currently available to the management, and do not represent a promise or guarantee to achieve those forecasts. Various uncertain factors could cause actual results to differ, such as changes in the business environment and fluctuation of foreign exchange rates. If a significant event occurs that requires the forecasts to be revised, the Company will disclose it in a timely manner.

(4) Litigation

Product liability litigation regarding pioglitazone-containing products

The Company, Takeda Pharmaceuticals U.S.A., Inc. (“TPUSA”), and certain Company Affiliates located in the U.S. have been named as defendants in lawsuits pending in U.S. federal and state courts in which plaintiffs allege to have developed bladder cancer or other injuries as a result of taking products containing type 2 diabetes treatment pioglitazone (U.S. brand name: ACTOS) (hereafter, “ACTOS” is used to refer generally to Takeda products containing pioglitazone). Eli Lilly & Co. (“Eli Lilly”) is a defendant in many of these lawsuits. Outside the U.S., lawsuits and claims have also been brought by persons claiming similar injuries.

On April 29, 2015 (U.S. time April 28), the Company and TPUSA reached agreement with plaintiff lawyers who are leaders in the litigation that is expected to resolve the vast majority of ACTOS product liability lawsuits pending against Takeda in the U.S. The settlement would cover all bladder cancer claims pending in any U.S. court as of the date of settlement, and claimants with unfiled claims represented by counsel as of the date of settlement and within three days thereafter are also eligible to participate. The settlement will become effective if 95% of current litigants and claimants opt in, and once that threshold is achieved, Takeda agrees to pay 2.37 billion USD into a settlement fund. That figure will rise to 2.4 billion USD if more than 97% of the current litigants and claimants opt to participate in the settlement. Under the settlement, current litigants and claimants who meet prescribed criteria would receive payouts from the fund. At present, Takeda is continuing to receive applications from litigants and claimants who wish to participate in the settlement. The Company will make an announcement once this is completed.

Takeda believes that the claims made in this litigation are without merit, and does not admit liability. Takeda believes that the company acted responsibly with regard to ACTOS. Takeda will continue to vigorously defend through all available legal means any cases that continue or are newly filed after the settlement.

(5) Other

Investigator-led study of anti-hypertensive treatment (CASE-J study)

In June 2015, Takeda received an order to improve business operation from the Japanese Ministry of Health, Labour and Welfare (MHLW) deeming that promotional materials based on the results of the investigator led CASE-J study of anti-hypertensive treatment BLOPRESS targeting healthcare professionals were applicable as misleading advertisements prohibited under the Pharmaceutical and Medical Device Act of Japan. In July 2015, Takeda submitted an improvement plan of business operation to the MHLW in response to this order.

From August 2015, in order to further improve the review structure for promotional materials, etc., Takeda has appointed an attorney from a law firm as an external expert member of the internal review committee, to strengthen the legal review and to increase objectivity by providing an external perspective. Additionally, all promotional materials that will be shared with healthcare professionals and training materials for sales representatives will be subject to review, and under the new review committee structure, Takeda will also strengthen its review of previously created promotional materials, updating them based on the latest knowledge. Also, there will be improvement in the training and education of employees creating promotional materials, their managers, and members of the review committee.

As a result of receiving the order to improve business operation from the MHLW, in July 2015, Takeda was dismissed from its position as Vice President of the Japan Pharmaceutical Manufacturers Association.

Each and every one of Takeda's employees and its management are deeply mindful of all stakeholders, particularly those patients and healthcare professionals awaiting our products. Our united effort is to restore trust from our stakeholders.

2. Additional Information in Summary

(1) Changes in significant subsidiaries during the period (changes in specified subsidiaries resulting in the change in consolidation scope):

No applicable event occurred during the period.

(2) Changes in accounting policies and changes in accounting estimates

The significant accounting policies adopted for the condensed interim consolidated financial statements are the same as those for the fiscal year ended March 31, 2015 with the exception of the items described below.
The Companies calculated income tax expenses for the three month period ended June 30, 2015, based on the estimated average annual effective tax rate.

(Changes in accounting policies)
The accounting standard applied by the Companies effective from the first quarter ended June 30, 2015 is as follows.

IFRS		Description of new standards, interpretations and amendments
IAS 19	Employee Benefits	Amendment to the accounting for contributions from employees and third parties to defined benefit plans

The above standard does not have a material impact on the condensed interim consolidated financial statements.

3. Condensed Interim Consolidated Financial Statements [IFRS]

(1) Condensed Interim Consolidated Statement of Operations

(Million JPY)

	Three month period ended June 30, 2014	Three month period ended June 30, 2015
Revenue	411,148	446,295
Cost of sales	(118,039)	(121,121)
Gross profit	293,109	325,174
Selling, general and administrative expenses	(136,581)	(161,694)
Research and development expenses	(75,155)	(80,991)
Amortization and impairment losses on intangible assets associated with products	(30,759)	(33,380)
Other operating income	24,125	7,410
Other operating expenses	(11,051)	(6,961)
Operating profit	63,689	49,559
Finance income	3,960	4,153
Finance expenses	(8,588)	(5,799)
Share of profit of associates accounted for using the equity method	929	808
Profit before tax	59,989	48,721
Income tax expenses	(25,679)	(23,292)
Net profit for the period	34,310	25,429
Attributable to:		
Owners of the Company	33,399	24,583
Non-controlling interests	911	846
Net profit for the period	34,310	25,429
Earnings per share (JPY)		
Basic earnings per share	42.40	31.32
Diluted earnings per share	42.36	31.12

(2) Condensed Interim Consolidated Statement of Operations and Other Comprehensive Income

(Million JPY)

	Three month period ended June 30, 2014	Three month period ended June 30, 2015
Net profit for the period	34,310	25,429
Other comprehensive income		
Items that will not be reclassified to profit or loss		
Remeasurements of defined benefit plans	(2,318)	6,818
	(2,318)	6,818
Items that may be reclassified subsequently to profit or loss		
Exchange differences on translation of foreign operations	(31,862)	72,584
Net changes on revaluation of available-for-sale financial assets	1,899	15,336
Cash flow hedges	(396)	217
	(30,359)	88,136
Other comprehensive income for the period, net of tax	(32,677)	94,954
Total comprehensive income for the period	1,633	120,383
Attributable to:		
Owners of the Company	1,315	119,255
Non-controlling interests	318	1,127
Total comprehensive income for the period	1,633	120,383

(3) Condensed Interim Consolidated Statement of Financial Position

(Million JPY)

	As of March 31, 2015	As of June 30, 2015
ASSETS		
NON-CURRENT ASSETS		
Property, plant and equipment	526,162	526,127
Goodwill	821,911	858,819
Intangible assets	939,381	950,985
Investment property	30,218	30,222
Investments accounted for using the equity method	10,425	11,315
Other financial assets	241,323	270,229
Other non-current assets	52,192	52,691
Deferred tax assets	154,506	148,983
Total non-current assets	2,776,120	2,849,369
CURRENT ASSETS		
Inventories	262,354	277,629
Trade and other receivables	444,681	461,222
Other financial assets	61,275	61,519
Income taxes recoverable	22,148	18,608
Other current assets	63,225	75,527
Cash and cash equivalents	652,148	576,404
Subtotal	1,505,830	1,470,910
Assets held for sale	14,243	570
Total current assets	1,520,072	1,471,481
Total assets	4,296,192	4,320,850

(Million JPY)

	As of March 31, 2015	As of June 30, 2015
LIABILITIES AND EQUITY		
LIABILITIES		
NON-CURRENT LIABILITIES		
Bonds and loans	629,416	633,184
Other financial liabilities	70,105	77,681
Net defined benefit liabilities	91,686	86,378
Provisions	47,075	42,888
Other non-current liabilities	78,778	77,431
Deferred tax liabilities	156,132	160,719
Total non-current liabilities	1,073,191	1,078,280
CURRENT LIABILITIES		
Bonds and loans	99,965	99,974
Trade and other payables	170,782	172,898
Other financial liabilities	42,105	36,744
Income taxes payable	41,071	56,417
Provisions	418,587	425,795
Other current liabilities	238,469	219,122
Subtotal	1,010,978	1,010,949
Liabilities held for sale	5,846	—
Total current liabilities	1,016,824	1,010,949
Total liabilities	2,090,016	2,089,229
EQUITY		
Share capital	64,044	64,212
Share premium	59,575	57,025
Treasury shares	(18,203)	(36,147)
Retained earnings	1,601,326	1,561,990
Other components of equity	430,305	518,159
Equity attributable to owners of the Company	2,137,047	2,165,238
Non-controlling interests	69,129	66,383
Total equity	2,206,176	2,231,621
Total liabilities and equity	4,296,192	4,320,850

(4) Condensed Interim Consolidated Statement of Changes in Equity

Three month period ended June 30, 2014 (From April 1 to June 30, 2014)

(Million JPY)

	Equity attributable to owners of the Company					
					Other components of equity	
	Share capital	Share premium	Treasury shares	Retained earnings	Exchange differences on translation of foreign operations	Net changes on revaluation of available-for-sale financial assets
As of April 1, 2014	63,562	39,866	(621)	1,901,307	406,151	60,771
Net profit for the period				33,399		
Other comprehensive income					(31,264)	1,882
Comprehensive income for the period	—	—	—	33,399	(31,264)	1,882
Issuances of new shares						
Acquisitions of treasury shares			(16,001)			
Disposals of treasury shares		(0)	1			
Dividends				(71,060)		
Changes in the ownership interest in subsidiaries				(7,901)		
Transfers from other components of equity				(2,306)		
Share-based payments		211				
Put options written on non-controlling interests		11,277				
Total transactions with owners	—	11,487	(16,001)	(81,266)	—	—
As of June 30, 2014	63,562	51,354	(16,621)	1,853,441	374,887	62,653

	Equity attributable to owners of the Company				Non-controlling interests	Total equity
	Other components of equity			Total		
	Cash flow hedges	Remeasurements of defined benefit plans	Total			
As of April 1, 2014	(298)	—	466,624	2,470,739	69,896	2,540,635
Net profit for the period			—	33,399	911	34,310
Other comprehensive income	(396)	(2,306)	(32,084)	(32,084)	(593)	(32,677)
Comprehensive income for the period	(396)	(2,306)	(32,084)	1,315	318	1,633
Issuances of new shares			—	—		—
Acquisitions of treasury shares			—	(16,001)		(16,001)
Disposals of treasury shares			—	1		1
Dividends			—	(71,060)	(717)	(71,776)
Changes in the ownership interest in subsidiaries			—	(7,901)	(4,079)	(11,980)
Transfers from other components of equity		2,306	2,306	—		—
Share-based payments			—	211		211
Put options written on non-controlling interests			—	11,277		11,277
Total transactions with the owners	—	2,306	2,306	(83,473)	(4,796)	(88,269)
As of June 30, 2014	(694)	—	436,846	2,388,581	65,417	2,453,998

Three month period ended June 30, 2015 (From April 1 to June 30, 2015)

(Million JPY)

	Equity attributable to owners of the Company					
					Other components of equity	
	Share capital	Share premium	Treasury shares	Retained earnings	Exchange differences on translation of foreign operations	Net changes on revaluation of available-for-sale financial assets
As of April 1, 2015	64,044	59,575	(18,203)	1,601,326	355,692	75,685
Net profit for the period				24,583		
Other comprehensive income					72,204	15,433
Comprehensive income for the period	—	—	—	24,583	72,204	15,433
Issuances of new shares	168	168				
Acquisitions of treasury shares			(22,300)			
Disposals of treasury shares		0	1			
Dividends				(70,738)		
Changes in the ownership interest in subsidiaries						
Transfers from other components of equity				6,818		
Share-based payments		(2,717)	4,355			
Put options written on non-controlling interests						
Total transactions with owners	168	(2,549)	(17,944)	(63,920)	—	—
As of June 30, 2015	64,212	57,025	(36,147)	1,561,990	427,896	91,119

	Equity attributable to owners of the Company				Non-controlling interests	Total equity
	Other components of equity			Total		
	Cash flow hedges	Remeasurements of defined benefit plans	Total			
As of April 1, 2015	(1,073)	—	430,305	2,137,047	69,129	2,206,176
Net profit for the period			—	24,583	846	25,429
Other comprehensive income	217	6,818	94,672	94,672	282	94,954
Comprehensive income for the period	217	6,818	94,672	119,255	1,127	120,382
Issuances of new shares			—	335		335
Acquisitions of treasury shares			—	(22,300)		(22,300)
Disposals of treasury shares			—	1		1
Dividends			—	(70,738)	(571)	(71,309)
Changes in the ownership interest in subsidiaries			—	—	(3,303)	(3,303)
Transfers from other components of equity		(6,818)	(6,818)	—		—
Share-based payments			—	1,638		1,638
Put options written on non-controlling interests			—	—		—
Total transactions with the owners	—	(6,818)	(6,818)	(91,064)	(3,874)	(94,937)
As of June 30, 2015	(856)	—	518,159	2,165,238	66,383	2,231,621

(5) Notes to Condensed Interim Consolidated Financial Statements

(Going Concern Assumption)

Three month period ended June 30, 2015 (April 1 to June 30, 2015)

No events to be noted for this purpose.

(Significant Changes in Equity Attributable to Owners of the Company)

Three month period ended June 30, 2015 (April 1 to June 30, 2015)

No events to be noted for this purpose.

(Segment Information)

1. Revenues and operating profit by reportable segment and other information

Three month period ended June 30, 2014 (April 1 to June 30, 2014)

(Million JPY)

	Reportable Segments			Total	Condensed interim consolidated financial statements
	Ethical Drugs	Consumer Healthcare	Other		
Revenues	372,403	16,884	21,861	411,148	411,148
Operating profit	34,560	5,688	23,440	63,689	63,689
			Finance income		3,960
			Finance expenses		(8,588)
			Share of profit of associates accounted for using the equity method		929
			Profit before tax		59,989

Three month period ended June 30, 2015 (April 1 to June 30, 2015)

(Million JPY)

	Reportable Segments			Total	Condensed interim consolidated financial statements
	Ethical Drugs	Consumer Healthcare	Other		
Revenues	407,811	19,427	19,057	446,295	446,295
Operating profit	34,858	7,639	7,062	49,559	49,559
			Finance income		4,153
			Finance expenses		(5,799)
			Share of profit of associates accounted for using the equity method		808
			Profit before tax		48,721

2. Geographic Information

Revenues

(Million JPY)

	Japan	United States	Europe and Canada	Russia/ CIS	Latin America	Asia	Others	Total
Three month period ended June 30, 2014	175,421	89,417	77,393	17,347	19,201	22,826	9,543	411,148
Three month period ended June 30, 2015	170,917	123,902	77,474	15,764	18,445	30,877	8,917	446,295

(Note)

1. Revenues are attributable to countries or regions based on the customer location.
2. "Others" region includes Middle East, Oceania and Africa.

(Breakdown of Revenues)

Three month period ended June 30, 2014 (April 1 to June 30, 2014)

(Million JPY)

Ethical Drugs			Consumer healthcare	Other	Condensed interim consolidated statement of income	[Royalties]
(Japan)	(Overseas)	Subtotal				
137,993	234,410	372,403	16,884	21,861	411,148	[13,493]

Three month period ended June 30, 2015 (April 1 to June 30, 2015)

(Million JPY)

Ethical Drugs			Consumer healthcare	Other	Condensed interim consolidated statement of income	[Royalties]
(Japan)	(Overseas)	Subtotal				
135,034	272,778	407,811	19,427	19,057	446,295	[14,079]

(Significant Subsequent Events)

No events to be noted for this purpose.

4. Supplemental Information

(1) Ethical Drugs Revenues [Consolidated]

(Billion JPY)

	Three month period ended June 30, 2014	Three month period ended June 30, 2015	Change over the same period of the previous year	
			Amount	Increase (decrease) in percent
Domestic revenues	136.2	133.1	(3.1)	(2.3%)
Overseas revenues	219.7	259.0	39.3	17.9%
United States	84.7	118.6	33.9	40.0%
Europe and Canada	69.3	70.7	1.5	2.1%
Russia/CIS	17.0	15.4	(1.5)	(9.1%)
Latin America	18.3	17.6	(0.7)	(3.7%)
Asia	21.9	28.6	6.7	30.5%
Others	8.6	8.1	(0.5)	(5.9%)
Royalty Income and Service Income	16.5	15.8	(0.8)	(4.7%)
Domestic	1.8	2.0	0.1	7.9%
Overseas	14.7	13.8	(0.9)	(6.3%)
Total revenues	372.4	407.8	35.4	9.5%

（Note）"Others" region includes Middle East, Oceania and Africa.

Ratio of Overseas sales	62.9%	66.9%

Foreign exchange rates (Reference)

(JPY)

	Three month period ended June 30, 2014	Three month period ended June 30, 2015	Increase(decrease)
USD average rate	102.3	121.0	18.8
EUR average rate	140.4	131.8	(8.6)

(2) Ethical Drugs: Global major products' sales [Consolidated]

(Billion JPY)

	Indication	Three month period ended June30, 2014	Three month period ended June 30, 2015	Change over the same period of the previous year	
				Amount	Increase (decrease) in percent
Velcade	Multiple myeloma	35.3	42.3	7.0	19.9%
Leuprorelin	Prostate cancer, breast cancer and endometriosis	29.6	30.9	1.3	4.5%
Lansoprazole	Peptic ulcers	25.5	25.9	0.4	1.7%
Pantoprazole	Peptic ulcers	25.8	24.3	(1.5)	(6.0%)
Candesartan	Hypertension	36.5	22.7	(13.8)	(37.8%)
Dexilant	Acid reflux disease	12.7	18.8	6.2	48.6%
Entyvio	Ulcerative colitis and Crohn's disease	0.4	16.2	15.7	－%
Nesina	Diabetes	10.8	12.2	1.4	13.1%
Colcrys	Gout	14.3	11.2	(3.2)	(22.0%)
Uloric	Gout and Hyperuricemia	6.7	10.0	3.3	49.1%
Amitiza	Constipation	6.6	9.4	2.9	43.6%
Pioglitazone	Diabetes	12.3	7.3	(5.1)	(40.9%)
Adcetris	Malignant Lymphoma	5.1	6.8	1.8	35.2%
Calcium	Calcium	4.9	4.8	(0.1)	(1.9%)
Actovegin	Cerebral vascular disorders and stroke	4.7	4.6	(0.1)	(2.2%)
Tachosil	Haemostasis	4.4	4.3	(0.1)	(3.2%)

(Note) Sales amount includes royalty income and service income.

(3) Ethical Drugs: Overseas major products' sales (Regional basis)

(Billion JPY)

Product name	Regional	Three month period ended June 30, 2014	Three month period ended June 30, 2015	Change over the same period of the previous year	
				Amount	Increase (decrease) in percent
Entyvio	United States	0.4	12.0	11.6	−%
(Ulcerative colitis and	Europe and Canada	0.0	3.9	3.9	−%
Crohn's disease)	Emerging Markets	−	0.2	0.2	−%
	Overseas - total	0.4	16.2	15.7	−%
Pantoprazole	United States	1.7	1.7	0.0	1.8%
(Peptic ulcers)	Europe and Canada	12.6	11.8	(0.8)	(6.2%)
	Emerging Markets	11.5	10.7	(0.8)	(6.9%)
	Overseas - total	25.8	24.3	(1.5)	(6.0%)
Leuprorelin	United States	3.3	4.7	1.4	42.9%
(Prostate cancer, breast	Europe and Canada	8.9	8.7	(0.2)	(2.3%)
cancer and endometriosis)	Emerging Markets	3.0	4.1	1.2	39.0%
	Overseas - total	15.2	17.5	2.4	15.6%
Lansoprazole	United States	6.0	9.1	3.0	50.5%
(Peptic ulcers)	Europe and Canada	3.2	3.1	(0.0)	(0.6%)
	Emerging Markets	2.3	2.7	0.4	18.5%
	Overseas - total	11.5	14.9	3.4	30.0%
Candesartan (Hypertension)	Overseas - total	7.6	6.6	(1.0)	(12.8%)

(Note)1. This table shows major overseas products revenues classified as "United States," "Europe and Canada" and "Emerging Markets (Latin America, Russia/CIS, Asia and Other regions)" and does not include revenues in Japan.

2. The revenues of Candesartan are shown in one area (Overseas - total), because export revenues are recorded under a single route.

3. Sales amount includes royalty income and service income.

(4) Ethical Drugs: US major products' sales (in USD)

(Million USD)

Product name	Launched Year	Indication	Three month period ended June 30, 2014	Three month period ended June 30, 2015	Change over the same period of the previous year	
					Amount	Increase (decrease) in percent
Velcade	2008	Multiple myeloma	251	276	24	9.7%
Dexilant	2009	Acid reflux disease	108	135	27	25.1%
Entyvio	2014	Ulcerative colitis and Crohn's disease	4	99	95	−%
Colcrys	2012	Gout	140	92	(48)	(34.2%)
Uloric	2009	Gout and Hyperuricemia	64	81	17	26.3%
Amitiza	2006	Constipation	64	77	13	20.7%
Prevacid (lansoprazole)	1995	Peptic ulcers	57	73	16	27.7%
Brintellix	2014	Major depressive disorder	22	42	20	88.1%
Contrave	2014	Obesity	−	16	16	−%

(Note) Sales amount does not include royalty income and service income.

(5) Ethical Drugs: Japan major products' sales

(Billion JPY)

Product name	Launched Year/Month	Indication	Three month period ended June 30, 2014	Three month period ended June 30, 2015	Change over the same period of the previous year	
					Amount	Increase (decrease) in percent
Blopress (candesartan)	1999/6	Hypertension	28.8	16.1	(12.8)	(44.3%)
Azilva	2012/5	Hypertension	9.7	14.1	4.4	45.1%
Leuplin (leuprorelin)	1992/9	Prostate cancer, breast cancer and endometriosis	14.4	13.3	(1.0)	(7.3%)
Takepron (lansoprazole)	1992/12	Peptic ulcers	14.0	11.0	(3.0)	(21.4%)
Enbrel	2005/3	Rheumatoid arthritis	9.4	10.4	1.0	10.3%
Nesina	2010/6	Diabetes	9.7	9.5	(0.2)	(2.3%)
Lotriga	2013/1	Hyperlipidemia	1.9	5.0	3.1	168.4%
Vectibix	2010/6	Colorectal cancer	4.3	4.7	0.4	9.0%
Reminyl	2011/3	Alzheimer-type dementia	2.9	3.9	1.0	36.4%
Benet	2002/5	Osteoporosis	2.6	2.5	(0.1)	(3.6%)
Basen	1994/9	Diabetes	3.1	2.4	(0.7)	(23.2%)
Actos (pioglitazon)	1999/12	Diabetes	3.1	2.4	(0.7)	(23.2%)
Rozerem	2010/7	Insomnia	1.5	1.8	0.3	21.0%
Adcetris	2014/4	Malignant Lymphoma	0.6	0.8	0.2	30.5%
Takecab	2015/2	Acid-related Diseases	—	0.5	0.5	—%

(6) Consumer Healthcare: Major products' sales

(Billion JPY)

Product name	Three month period ended June 30, 2014	Three month period ended June 30, 2015	Change over the same period of the previous year	
			Amount	Increase (decrease) in percent
Alinamin tablets	4.7	6.9	2.2	47.9%
Alinamin health tonics	4.3	4.0	(0.3)	(7.7%)
Biofermin	1.9	2.2	0.3	16.1%
Benza	1.1	1.2	0.1	8.0%
Borraginol	0.9	1.1	0.2	17.0%

(7) Development activities

This table primarily shows the indications for which we will actively pursue approval. We are also conducting additional studies of certain assets to examine their potential for use in further indications.

■ US/EU/Jpn

Development code <generic name> Brand name (country / region)	Drug Class (administration route)	Indications	Stage		In-house/ In-license
MLN9708 <ixazomib>	Proteasome inhibitor (oral)	Relapsed or refractory multiple myeloma	US EU Jpn	Filed (Jul '15) P-III P-III	In-house
		Previously untreated multiple myeloma	US EU Jpn	P-III P-III P-III	
		Maintenance therapy in patients with newly diagnosed multiple myeloma following autologous stem cell transplant	US EU Jpn	P-III P-III P-III	
		Maintenance therapy in patients with newly diagnosed multiple myeloma not treated with stem cell transplant	US EU Jpn	P-III P-III P-III	
		Relapsed or refractory primary (AL) amyloidosis	US EU	P-III P-III	
		Solid tumors	US	P-I	
TAK-816	Hib vaccine (injection)	Prevention of infectious disease caused by Haemophilus influenzae type b (Hib)	Jpn	Filed (Sep '13)	In-license (GSK)
<glatiramer acetate>	Immunomodulator (injection)	Relapse prevention of multiple sclerosis	Jpn	Filed (Dec '14)	In-license (Teva)
MLN0002 <vedolizumab> Entyvio® (US, EU)	Humanized monoclonal antibody against α4β7 integrin (injection)	Ulcerative colitis	Jpn	P-III	In-house
		Crohn's disease	Jpn	P-III	
Lu AA21004 <vortioxetine> Brintellix® (US)	Multimodal anti-depressant (oral)	Major depressive disorder	Jpn	P-III	In-license (Lundbeck)
AMG 386 <trebananib>	Anti-angiopoietin peptibody (injection)	Ovarian cancer	Jpn	P-III	In-license (Amgen)
TVP-1012 <rasagiline>	Monoamine oxidase B (MAO-B) inhibitor (oral)	Parkinson's disease	Jpn	P-III	In-license (Teva)
MLN8237 <alisertib>	Aurora A kinase inhibitor (oral)	Small cell lung cancer	US EU	P-II P-II	In-house
		Non-Hodgkin lymphoma	Jpn	P-I	
		Solid tumors	Jpn	P-I	
TAK-264[*1] **< - >**	Antibody-Drug Conjugate targeting GCC (injection)	Gastric cancer	US EU Jpn	P-II P-II P-I	In-house
		Pancreatic cancer	US EU	P-II P-II	
TAK-385 <relugolix>	LH-RH antagonist (oral)	Prostate cancer	US EU Jpn	P-II P-II P-I	In-house
		Endometriosis	Jpn	P-II	
		Uterine fibroids	Jpn	P-II	
TAK-228[*2] **< - >**	mTORC1/2 inhibitor (oral)	Breast cancer	US EU	P-II P-II	In-house
		Renal cancer	US	P-II	
		Endometrial cancer	US	P-II	
		Solid tumors	-	P-I	

*1 Formerly known as MLN0264
*2 Formerly known as MLN0128

Development code/product name <generic name>	Drug Class (administration route)	Indications	Stage		In-house/ In-license
TAK-272 < - >	Direct renin inhibitor (oral)	Early stage diabetic nephropathy	Jpn	P-II	In-house
		Hypertension	-	P-I	
TAK-003	Tetravalent dengue vaccine (injection)	Prevention of dengue fever caused by dengue virus	-	P-II	In-house
TAK-214	Norovirus vaccine (injection)	Prevention of acute gastroenteritis (AGE) caused by norovirus	-	P-II	In-house
TAK-114 < - >	Pro-inflammatory cytokine inhibitor (oral)	Ulcerative colitis	US EU Jpn	P-II P-II P-I	In-license (Natrogen)
MT203 <namilumab>	GM-CSF monoclonal antibody (injection)	Psoriasis	EU	P-II	In-licence (Amgen)
		Rheumatoid arthritis	EU Jpn	P-II P-I	
TAK-850	Influenza vaccine (injection)	Prevention of influenza disease caused by influenza virus subtype A and B contained in the vaccine	Jpn	P-I/II	In-license (Baxter)
TAK-063 < - >	PDE10A inhibitor (oral)	Schizophrenia	-	P-I	In-house
TAK-659 < - >	SYK kinase inhibitor (oral)	Solid tumors, Hematologic malignancies	-	P-I	In-house
TAK-233 < - >	(oral)	-	-	P-I	In-house
TAK-935 < - >	CH24H inhibitor (oral)	Diseases related to glutamate excitotoxicity	-	P-I	In-house
TAK-058 < - >	5-HT3 receptor antagonist (oral)	Schizophrenia, especially cognitive impairment associated with schizophrenia	-	P-I	In-house
TAK-079 < - >	Cytolytic monoclonal antibody (injection)	Rheumatoid arthritis, Systemic lupus erythematosus	-	P-I	In-house
TAK-020 < - >	Bruton's tyrosine kinase inhibitor (oral)	Rheumatoid arthritis	-	P-I	In-house
TAK-021	EV71 vaccine (injection)	Prevention of hand, foot and mouth disease caused by enterovirus 71	-	P-I	In-house
TAK-924*3 **< - >**	NEDD 8 activating enzyme inhibitor (injection)	Advanced malignancies, Acute myeloid leukemia	-	P-I	In-house
TAK-117*4 **< - >**	PI3Kα isoform inhibitor (oral)	Solid tumors, Non-small cell lung cancer	-	P-I	In-house
TAK-243*5 **< - >**	UAE inhibitor (injection)	Solid tumors	-	P-I	In-house
TAK-648 < - >	PDE4 inhibitor (oral)	-	-	P-I	In-house
TAK-915 < - >	PDE2A inhibitor (oral)	Negative symptoms and/or cognitive impairment associated with schizophrenia	-	P-I	In-house
TAK-580*6 **< - >**	pan-Raf kinase inhibitor (oral)	Solid tumors	-	P-I	In-license (Sunesis)
Lu AA24530 < - >	Multimodal anti-depressant (oral)	Major depressive disorder, Generalized anxiety disorder	US Jpn	P-I P-I	In-license (Lundbeck)

*3 Formerly known as MLN4924
*4 Formerly known as MLN1117
*5 Formerly known as MLN7243
*6 Formerly known as MLN2480

Development code/ product name <generic name>	Drug Class (administration route)	Indications	Stage		In-house/ In-license
AMG 403 <fulranumab>	Human monoclonal antibody against human Nerve Growth Factor (NGF) (injection)	Pain	Jpn	P-I	In-license (Amgen)

■ Additional indications/formulations of approved compounds

Development code <generic name> Brand name (country / region)	Drug Class	Indications or formulations	Stage		In-house/ In-license
TAP-144-SR <leuprorelin acetate> Leuplin® (Jpn) Lupron Depot® (US) Enantone®, etc. (EU)	LH-RH agonist	Prostate cancer, Premenopausal breast cancer (6-month formulation)	Jpn	Filed (Sep '14)	In-house
TAK-390MROD <dexlansoprazole> Dexilant® (US)	Proton pump inhibitor	Acid-related diseases (orally disintegrating tablet)	US	Filed (Mar '15)	In-house
SGN-35 <brentuximab vedotin> Adcetris® (EU, Jpn)	CD30 monoclonal antibody-drug conjugate	Post-ASCT Hodgkin lymphoma	EU	Filed (Mar '15)	In-license (Seattle Genetics)
		Relapsed cutaneous T-cell lymphoma	EU	P-III	
		Front line Hodgkin lymphoma	EU Jpn	P-III P-III	
		Front line mature T-cell lymphoma	EU Jpn	P-III P-III	
SYR-322 <alogliptin> Nesina® (US, Jpn) Vipidia® (EU)	DPP-4 inhibitor	Type 2 diabetes (fixed-dose combination with metformin)	Jpn	P-III	In-house
TAK-536 <azilsartan> Azilva® (Jpn)	Angiotensin II receptor blocker	Hypertension (fixed-dose combination with amlodipine and hydrochlorothiazide)	Jpn	P-III	In-house
AD-4833/TOMM40	Insulin sensitizer/ Biomarker assay	Delay of onset of mild cognitive impairment due to Alzheimer's disease	US EU	P-III P-III	In-license (Zinfandel)
Lu AA21004 <vortioxetine> Brintellix® (US)	Multimodal anti-depressant	Generalized anxiety disorder	US	P-III	In-license (Lundbeck)
		Attention Deficit Hyperactivity Disorder (ADHD) in adult patients	US	P-II	
<lubiprostone> Amitiza® (US)	Chloride channel activator	New formulation	US	P-III	In-license (Sucampo)
		Pediatric functional constipation	US	P-III	
<febuxostat XR> Uloric® (US)	Non-purine, selective xanthine oxidase inhibitor	Hyperuricemia (extended-release formulation)	US	P-III	In-license (Teijin)
NE-58095NF <risedronate> Benet® (Jpn)	Bone resorption inhibitor	Osteoporosis (additional formulation; change of the dosage and administration)	Jpn	P-II/III	In-license (Ajinomoto Pharmaceuticals)
MLN0002 <vedolizumab> Entyvio® (US, EU)	Humanized monoclonal antibody against α4β7 integrin	Ulcerative colitis, Crohn's disease (subcutanous formulation)	-	P-I	In-house

■ Recent progress in stage **Progress in stage since release of FY2014 results (May 15th, 2015)**

Development code <generic name>	Indications	Country/Region	Progress in stage
MLN9708 <ixazomib>	Relapsed or refractory multiple myeloma	US	Filed (Jul '15)
TAK-228 < - >	Renal cancer	US	P-II
TAK-228 < - >	Endometrial cancer	US	P-II
TAK-648 < - >	-	-	P-I
TAK-915 < - >	Negative symptoms and/or cognitive impairment associated with schizophrenia	-	P-I

■ Discontinued projects **Discontinued since release of FY2014 results (May 15th, 2015)**

Development code <generic name>	Indications (Stage)	Reason
TAK-137 < - >	Psychiatric disorders, Neurological diseases (P-I)	Pharmacokinetic variability led to decrease in safety margin.
TAK-733 < - >	Solid tumors (P-I)	Development terminated based on a strategic portfolio decision.

■ Filings and Approvals in Brazil, China & Russia

Takeda is steadily progressing its pipeline assets through the filing and approval process on a global scale, including in emerging markets. This table shows filings and approvals in the key emerging markets of Brazil, China & Russia.

Country	Development code/generic name (stage)
Brazil	SYR-322/metformin (Filed Jul '13), SYR-322/pioglitazone (Filed Dec '13), TAK-375*7 (Filed Mar '14), MLN0002 (Approved May '15)
China	SGN-35 (Filed May '13)
Russia	SYR-322/metformin (Filed Mar '14), SGN-35 (Filed May '14), MLN0002 (Filed Jun '15)

*7 **TAK-375 <ramelteon>** MT1/MT2 receptor agonist (oral) for the treatment of insomnia